[开放获取]    中国银屑病生物制剂治疗指南（2021）

doi:10.35541/cjd.20210643

Abstract

Abstract: 【Abstract】 Biologic agents are increasingly used in the treatment of psoriasis, and have played an active role in addressing moderate to severe, refractory and special types of psoriasis. Biologic agents that have been approved for marketing and used in the treatment of psoriasis in China include 7 agents of 3 major categories, namely tumor necrosis factor-α inhibitors, interleukin 12/23 inhibitors and interleukin 17A inhibitors. How to use biologic agents in a rational, effective and safe way has become an issue of great concern in clinical practice. To this end, experts in the field of diagnosis and treatment of psoriasis and related fields in China developed this guideline based on Chinese and international research data, clinical experience, as well as characteristics of Chinese patients with psoriasis after in-depth discussions. This guideline provides specific guidance for clinicians in terms of application principles and methods of major biologic agents, efficacy and safety profiles, patient screening and monitoring, common problems and solutions, as well as considerations for their application in special populations.

Key words: Psoriasis, Biologic agents, Treatment, Guidelines

Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologic agents in China （2021）[J]. Chinese Journal of Dermatology, 2021, 54(12): 1033-1047.doi:10.35541/cjd.20210643

References ［75］

［1］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识（2019）［J］. 中华皮肤科杂志, 2019,52（12）:863⁃871. doi: 10.35541/cjd.20190892.
［2］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018简版）［J］. 中华皮肤科杂志, 2019,52（4）:223⁃230. doi: 10.3760/cma.j.issn.0412⁃4030.2019.04.001.
［3］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
［4］	Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate⁃to⁃severe psoriasis in adults［J］. J Eur Acad Dermatol Venereol, 2019,33（3）:464⁃483. doi: 10.1111/jdv.15340.
［5］	Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update［J］. Br J Dermatol, 2020,183（4）:628⁃637. doi: 10.1111/bjd.19039.
［6］	Poelman SM, Keeling CP, Metelitsa AI. Practical guidelines for managing patients with psoriasis on biologics: an update［J］. J Cutan Med Surg, 2019,23（1_suppl）:3S⁃12S. doi: 10.1177/12034 75418811347.
［7］	Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis （the 2019 version）［J］. J Dermatol, 2020,47（3）:201⁃222. doi: 10.1111/1346⁃8138.15196.
［8］	黄琼, 杨勤萍, 方栩, 等. 重组人II型肿瘤坏死因子受体⁃抗体融合蛋白治疗寻常性银屑病多中心、随机、双盲实验［J］. 中华皮肤科杂志, 2007,40（11）:655⁃658.
［9］	Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double⁃blind, placebo⁃controlled multicenter trial［J］. Chin Med J （Engl）, 2012,125（11）:1845⁃1851. doi: 10. 3760/cma.j.issn.0366⁃6999.2012.11.001.
［10］	Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque⁃type psoriasis: a randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol,2004,51（4）:534⁃542. doi: 10.1016/j.jaad.2004.02.021.
［11］	Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phase III, multicentre, double⁃blind trial［J］. Lancet, 2005,366（9494）:1367⁃1374. doi: 10.1016/S0140⁃6736（05）67566⁃6.
［12］	Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: results from a phase 3, randomized, placebo⁃controlled, double⁃blind study［J］. J Eur Acad Dermatol Venereol, 2017,31（1）:89⁃95. doi: 10.1111/jdv.13746.
［13］	Menter A, Tyring SK, Gordon K, et al. Adalimumabtherapy for moderate to severe psoriasis: a randomized, controlled phase III trial［J］. J Am Acad Dermatol, 2008,58（1）:106⁃115. doi: 10. 1016/j.jaad.2007.09.010.
［14］	Gordon K, Papp K, Poulin Y, et al. Long⁃term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open⁃label extension study for patients from REVEAL［J］. J Am Acad Dermatol, 2012,66（2）:241⁃251. doi: 10.1016/j.jaad.2010.12.005.
［15］	Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial［J］. Lancet, 2017,390（10089）:40⁃49. doi: 10.1016/S0140⁃6736（17）31189⁃3.
［16］	刘鸿伟, 胡雪英, 雷东春, 等. 阿达木单抗治疗重度斑块状银屑病的临床观察［J］. 中华皮肤科杂志, 2020,53（9）:744⁃746. doi: 10.35541/cjd.20190757.
［17］	Lanna C, Zangrilli A, Bavetta M, et al. Efficacy and safety of adalimumab in difficult⁃to⁃treat psoriasis［J］. Dermatol Ther, 2020,33（3）:e13374. doi: 10.1111/dth.13374.
［18］	Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 52⁃week results from a randomized, double⁃blind, placebo⁃controlled trial （PHOENIX 2）［J］. Lancet, 2008,371（9625）:1675⁃1684. doi: 10.1016/S0140⁃6736（08）60726⁃6.
［19］	Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in pediatric patients （≥6 to <12 years of age）: efficacy, safety, pharmacokinetic, and biomarker results from the open label CADMUS Jr study［J］. Br J Dermatol, 2020,183（4）:664⁃672. doi: 10.1111/bjd.19018.
［20］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［21］	Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double⁃blind, placebo⁃ and active comparator⁃controlled VOYAGE 2 trial［J］. J Am Acad Dermatol, 2017,76（3）:418⁃431. doi: 10.1016/j.jaad.2016. 11.042.
［22］	Reich K, Griffiths C, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials［J］. J Am Acad Dermatol, 2020,82（4）:936⁃945. doi: 10.1016/j.jaad.2019.11.040.
［23］	Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic⁃naive or had previously received TNF⁃α inhibitor treatment （DISCOVER⁃1）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1115⁃1125. doi: 10.1016/S0140⁃6736（20）30265⁃8.
［24］	Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic⁃naive patients with active psoriatic arthritis （DISCOVER⁃2）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1126⁃1136. doi: 10.1016/S0140⁃6736（20）30263⁃4.
［25］	Zhuang JY, Li JS, Zhong YQ, et al. Evaluation of short⁃term（16⁃week） effectiveness and safety of guselkumab in patients with psoriasis: a prospective real⁃life study on the Chinese population［J］. Dermatol Ther, 2021:e15054. doi: 10.1111/dth.15054.
［26］	Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（22）:2665⁃2673. doi: 10.1097/CM9.000000 0000001163.
［27］	Huang H, Cai ML, Hong XJ et al. Real⁃world data on the use of secukinumab as treatment for moderate⁃to⁃severe psoriasis in Chinese patients［J］. Eur J Dermatol, 2020,30（5）:554⁃560. doi:10.1684/ejd.2020.3878.
［28］	Zhao Y, Cai L, Liu XY, et al. Efficacy and safety of secukinumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: a real⁃life cohort study［J］. Chin Med J （Engl）, 2021,134（11）:1324⁃1328. doi: 10.1097/CM9.0000000000001 510.
［29］	Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med, 2016,375（4）:345⁃356. doi: 10.1056/NEJMoa1512711.
［30］	Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52⁃week, open⁃label, phase 3 study （UNCOVER⁃J）［J］. J Dermatol, 2017,44（4）:355⁃362. doi: 10.1111/1346⁃8138.13622.
［31］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris ⁃ Part 1: treatment and monitoring recommendations［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:2461⁃2498. doi: 10.1111/jdv.16915.
［32］	Nast A, Altenburg A, Augustin M, et al. German S3⁃Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm ⁃ Part 1: treatment goals and treatment recommendations［J］. J Dtsch Dermatol Ges, 2021,19（6）:934⁃150. doi: 10.1111/ddg.14508.
［33］	Lambert J, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history （BETA⁃PSO: Belgian Evidence⁃based Treatment Advice in Psoriasis; part 1）［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1654⁃1665. doi: 10.1111/jdv. 16684.
［34］	Lambert JLW, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders （BETA⁃PSO: Belgian Evidence⁃based Treatment Advice in Psoriasis; part 2）［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:1914⁃1923. doi: 10.1111/jdv.16683.
［35］	de la Cueva Dobao P, Notario J, Ferrándiz C, et al. Expert consensus on the persistence of biological treatments in moderate⁃to⁃severe psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（7）:1214⁃1223. doi: 10.1111/jdv.15600.
［36］	Podoswa⁃Ozerkovsky N, Amaya⁃Guerra M, Barba⁃Gómez JF, et al. Expert recommendations for biological treatment in patients with psoriasis［J］.Gac Med Mex, 2020,156（5）:446⁃453. doi: 10.24875/GMM.M20000441.
［37］	Lebwohl MG, Kircik L, Callis Duffin K, et al. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis［J］. J Am Acad Dermatol, 2013,69（3）:385⁃392. doi: 10.1016/j.jaad.2013.03.031.
［38］	Richard EG, Hönigsmann H. Phototherapy, psoriasis, and the age of biologics［J］. Photodermatol Photoimmunol Photomed, 2014,30（1）:3⁃7. doi: 10.1111/phpp.12088.
［39］	Torres AE, Lyons AB, Hamzavi IH, et al. Role of phototherapy in the era of biologics［J］. J Am Acad Dermatol, 2021,84（2）:479⁃485. doi: 10.1016/j.jaad.2020.04.095.
［40］	Armstrong AW, Bagel J, Van Voorhees AS, et al. Combining biologic therapies with other systemic treatments in psoriasis: evidence⁃based, best⁃practice recommendations from the Medical Board of the National Psoriasis Foundation［J］. JAMA Dermatol, 2015,151（4）:432⁃438. doi: 10.1001/jamadermatol. 2014.3456.
［41］	Liu LF, Chen JS, Gu J, et al. Etanercept biosimilar （recombinant human tumor necrosis factor⁃α receptor II: IgG Fc fusion protein） and methotrexate combination therapy in Chinese patients with moderate⁃to⁃severe plaque psoriasis: a multicentre, randomized, double⁃blind, placebo⁃controlled trial［J］. Arch Dermatol Res, 2020,312（6）:437⁃445. doi: 10.1007/s00403⁃019⁃02024⁃6.
［42］	Calzavara⁃Pinton PG, Sala R, Arisi M, et al. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque⁃type psoriasis［J］. Br J Dermatol, 2013,169（1）:130⁃136. doi: 10.1111/bjd.12277.
［43］	Wolf P, Hofer A, Weger W, et al. 311 nm ultraviolet B⁃accelerated response of psoriatic lesions in adalimumab⁃treated patients［J］. Photodermatol Photoimmunol Photomed, 2011,27（4）:186⁃189. doi: 10.1111/j.1600⁃0781.2011.00594.x.
［44］	Wolf P, Weger W, Legat FJ, et al. Treatment with 311⁃nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab⁃treated patients: a randomized intraindividual trial［J］. Br J Dermatol, 2012,166（1）:147⁃153. doi: 10.1111/j.1365⁃2133.2011.10616.x.
［45］	Dalaker M, Bonesrønning JH. Long⁃term maintenance treatment of moderate⁃to⁃severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort［J］. J Eur Acad Dermatol Venereol, 2009,23（3）:277⁃282. doi: 10.1111/j.1468⁃3083.2008.03039.x.
［46］	Menting SP, van Lümig PP, de Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one⁃year follow⁃up［J］. JAMA Dermatol, 2014,150（2）:130⁃136. doi: 10.1001/jamadermatol.2013.8347.
［47］	Adişen E, Karaca F, Gürer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents［J］. Clin Exp Dermatol, 2008,33（2）:164⁃166. doi: 10.1111/j.1365⁃2230. 2007.02673.x.
［48］	Krell JM. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept［J］. J Am Acad Dermatol, 2006,54（6）:1099⁃1101. doi: 10.1016/j.jaad.2005.08. 032.
［49］	Torres T, Tavares Bello R, Paiva Lopes MJ, et al. Portuguese recommendations for the treatment of psoriasis with biologic therapy［J］. Eur J Dermatol, 2020,30（6）:645⁃654. doi: 10.1684/ejd.2020.3945.
［50］	Rademaker M, Agnew K, Andrews M，et al. Psoriasis in those planning a family, pregnant or breast⁃feeding. The Australasian Psoriasis Collaboration［J］. Australas J Dermatol, 2018,59（2）:86⁃100. doi: 10.1111/ajd.12641.
［51］	Owczarek W, Walecka I, Lesiak A, et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines［J］. Postepy Dermatol Alergol, 2020,37（6）:821⁃830. doi: 10.5114/ada.2020. 102089.
［52］	Yeung J, Gooderham MJ, Grewal P, et al. Management of plaque psoriasis with biologic therapies in women of child⁃bearing potential consensus paper［J］. J Cutan Med Surg, 2020,24（1_suppl）:3S⁃14S. doi: 10.1177/1203475420928376.
［53］	Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities［J］. Paediatr Drugs, 2015,17（5）:373⁃384. doi: 10. 1007/s40272⁃015⁃0137⁃1.
［54］	Gatti J, Lindstrom J A, Beitz J. Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis［J］. Pediatr Dermatol, 2018,35（5）:688⁃689. doi: 10.1111/pde. 13557.
［55］	Fabrizi G, Guerriero C, Pagliarello C. Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 month⁃old child successfully treated with etanercept［J］. Eur J Dermatol, 2007,17（3）:245. doi: 10.1684/ejd.2007.0159.
［56］	Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF⁃α antagonists: a systematic review and meta⁃analysis of randomised controlled trials［J］. BMJ Open, 2017,7（3）:e012567. doi: 10.1136/bmjopen⁃2016⁃012567.
［57］	国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范（2020年版）的通知［EB/OL］. （2020⁃04⁃14）. https://www.sohu.com/a/387919909_771405.
［58］	Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin （IL）⁃17 and IL⁃23 inhibitors in psoriasis ⁃time for a paradigm change［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:824⁃834. doi: 10.1111/jdv.16866.
［59］	Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis［J］. JAMA Dermatol, 2021,157（1）:43⁃51. doi: 10.1001/jamadermatol. 2020.3257.
［60］	Shu D, Zhang Z, Zhou EY, et al. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL⁃17 inhibitors? A cohort study［J］. Dermatol Ther, 2020,33（6）: e14512. doi: 10.1111/dth.14512.
［61］	肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识［J］. 中华风湿病学杂志, 2013,17（8）:508⁃512. doi: 10.3760/cma.j.issn.1007⁃7480.2013.08.002.
［62］	Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions［J］. Gastroenterology, 2017,152（6）:1297⁃1309. doi: 10.1053/j.gastro. 2017.02.009
［63］	Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study［J］. Acta DermVenereol, 2018,98（9）:829⁃834. doi: 10. 2340/00015555⁃2989.
［64］	Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2020,156（4）:421⁃429. doi: 10.1001/jamadermatol. 2020.0024.
［65］	Elmets CA, Leonardi CL, Davis D, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities［J］. J Am Acad Dermatol, 2019,80（4）:1073⁃1113. doi: 10.1016/j.jaad.2018.11. 058.
［66］	Briukhovetska D, Dörr J, Endres S, et al. Interleukins in cancer: from biology to therapy［J］. Nat Rev Cancer, 2021,21（8）:481⁃499. doi: 10.1038/s41568⁃021⁃00363⁃z.
［67］	Zhao J, Chen X, Herjan T, et al. The role of interleukin⁃17 in tumor development and progression［J］. J Exp Med, 2020,217（1）:e20190297. doi: 10.1084/jem.20190297.
［68］	Yan J, Smyth MJ, Teng MWL. Interleukin （IL）⁃12 and IL⁃23 and their conflicting roles in cancer［J］. Cold Spring Harb Perspect Biol, 2018,10（7）:a028530. doi: 10.1101/cshperspect.a028530.
［69］	Peleva E, Exton LS, Kelley K, et al. Risk of cancer in patients with psoriasis on biological therapies: a systematic review［J］. Br J Dermatol, 2018,178（1）:103⁃113. doi: 10.1111/bjd.15830.
［70］	Plachouri KM, Georgiou S. Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus （HIV） infection, and pediatric psoriasis［J］. Int J Dermatol, 2019,58（9）:1008⁃1013. doi: 10. 1111/ijd.14436.
［71］	Kamiya K, Komine M, Ohtsuki M. Biologics for psoriasis during the COVID⁃19 pandemic［J］. J Clin Med, 2021,10（7）:1390. doi: 10.3390/jcm10071390.
［72］	Smith CH, Jabbar⁃Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017［J］. Br J Dermatol, 2017,177（3）:628⁃636. doi: 10.1111/bjd.15665.
［73］	Sacchelli L, Magnano M, Loi C, et al. The unforeseen during biotechnological therapy for moderate⁃to⁃severe psoriasis: how to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering［J］. Dermatol Ther, 2020,33（3）:e13411. doi: 10. 1111/dth.13411.
［74］	Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis （the 2013 version）［J］. J Dermatol, 2013, 40（9）:683⁃695. doi: 10.1111/1346⁃8138.12239.
［75］	Tsai TF, Hsieh TY, Chi CC, et al. Taiwan Rheumatology Association （TRA） and the Taiwanese Association for Psoriasis and Skin Immunology （TAPSI）. Recommendations for psoriatic arthritis management: a joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology［J］. J Formos Med Assoc, 2021, 120（3）:926⁃938. doi: 10.1016/j.jfma.2020.08.026.

[1]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482.
[2]	Hou Xiaoyuan, Wu Nanhui, Xu Mingyuan, Liu Yeqiang. A case of granuloma annulare treated with the JAK inhibitor baricitinib [J]. Chinese Journal of Dermatology, 2024, 57(5): 461-462.
[3]	Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475.
[4]	Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444.
[5]	China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417.
[6]	Mycology Group, Combination of Traditional and Western Medicine Dermatology, Chinese Antifungal-Resistant Dermatophytosis Expert Consensus Group. Expert consensus on the diagnosis, treatment, prevention and control of antifungal-resistant dermatophyte infections in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 418-425.
[7]	Ge Xinhong, Ma Yingdong, Jiao Yaning, Liu Lingling, Zhou Mei, Zi Wei, Li Bowen. Analysis of efficacy and safety of 532-nm picosecond laser in the treatment of early-stage facial seborrheic keratosis [J]. Chinese Journal of Dermatology, 2024, 57(4): 359-362.
[8]	Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 0(4): 20220278-e20220278.
[9]	Liu Yi, Qu Ying, Lei Wenzhi, Liu Xiaogang, Pan Weihua, Zhang Chao. Clinical efficacy of salt-packing therapy in the treatment of pyogenic granuloma [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230553-e20230553.
[10]	Ju Qiang, Li Jiaqi. Acne vulgaris revisited: from pathogenesis to treatment strategies [J]. Chinese Journal of Dermatology, 2024, 57(4): 289-294.
[11]	Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354.
[12]	Tian Jing, Deng Sisi, Song Zhiqiang . A comparison of clinical characteristics between atopic and non-atopic prurigo nodularis [J]. Chinese Journal of Dermatology, 2024, 57(4): 331-337.
[13]	Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578.
[14]	Wang Yukun, Liu Jie. Application of deep learning in non-neoplastic dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220660-e20220660.
[15]	Chen Xingyu, Yao Xu. Role of neutrophils in inflammatory dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220865-e20220865.

Guidelines for the treatment of psoriasis with biologic agents in China （2021）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［75］

Related Articles 15

Metrics

Comments

Recommended 10